Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Section A: Submissions for registration
The committee's advice was sought on six new pre-market applications for prescription medicines, as tabulated below.
| Number of applications | Application Type | Main consideration by ACM |
|---|---|---|
| 1 | Type A - New Chemical /Biological Entity/Biosimilar | For general consideration |
| 3 | Type C - Extension of indication | For consideration of broader indication with or without substantiating supportive evidence. |
| 2 | Type F - Major variation (New Dose Form/New Route of Administration) | For general consideration |
The committee's advice was also sought on one Category 3 application for a registered medicine.
Further details of the ACM discussions and advice associated with pre-market items are released within the Australian Public Assessment Reports (AusPARs) for each new active. Please note that there is a delay from when an application was considered at ACM, and the publication of the AusPAR. Browse all AusPARs.
Section B: Post-Market items referred for advice
No pharmacovigilance items were discussed.
Further information
For further information on the ACM, please visit Advisory Committee on Medicines or contact the ACM Secretary by email: ACM@health.gov.au.